Next Article in Journal
Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review
Next Article in Special Issue
Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset
Previous Article in Journal
ROS Production and Distribution: A New Paradigm to Explain the Differential Effects of X-ray and Carbon Ion Irradiation on Cancer Stem Cell Migration and Invasion
Previous Article in Special Issue
The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview

Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue

Istituto di Istologia ed Embriologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario “Agostino Gemelli”, IRCCS, 00168 Roma, Italy
Author to whom correspondence should be addressed.
Cancers 2019, 11(4), 469;
Received: 5 February 2019 / Revised: 19 March 2019 / Accepted: 26 March 2019 / Published: 3 April 2019
(This article belongs to the Special Issue Advances in Cancer Stem Cell Research)
PDF [676 KB, uploaded 17 April 2019]


Glioblastoma (GBM) is one of the most aggressive and lethal human brain tumors. At present, GBMs are divided in primary and secondary on the basis of the mutational status of the isocitrate dehydrogenase (IDH) genes. In addition, IDH1 and IDH2 mutations are considered crucial to better define the prognosis. Although primary and secondary GBMs are histologically indistinguishable, they retain distinct genetic alterations that account for different evolution of the tumor. The high invasiveness, the propensity to disperse throughout the brain parenchyma, and the elevated vascularity make these tumors extremely recidivist, resulting in a short patient median survival even after surgical resection and chemoradiotherapy. Furthermore, GBM is considered an immunologically cold tumor. Several studies highlight a highly immunosuppressive tumor microenvironment that promotes recurrence and poor prognosis. Deeper insight into the tumor immune microenvironment, together with the recent discovery of a conventional lymphatic system in the central nervous system (CNS), led to new immunotherapeutic strategies. In the last two decades, experimental evidence from different groups proved the existence of cancer stem cells (CSCs), also known as tumor-initiating cells, that may play an active role in tumor development and progression. Recent findings also indicated the presence of highly infiltrative CSCs in the peritumoral region of GBM. This region appears to play a key role in tumor growing and recurrence. However, until recently, few studies investigated the biomolecular characteristics of the peritumoral tissue. The aim of this review is to recapitulate the pathological features of GBM and of the peritumoral region associated with progression and recurrence. View Full-Text
Keywords: biomarkers; chemotherapy; microRNA; cancer stem cells; central nervous system; glioma; GBM; peritumoral tissue biomarkers; chemotherapy; microRNA; cancer stem cells; central nervous system; glioma; GBM; peritumoral tissue

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

D’Alessio, A.; Proietti, G.; Sica, G.; Scicchitano, B.M. Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue. Cancers 2019, 11, 469.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top